359 related articles for article (PubMed ID: 6367665)
1. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Surwit RS; Gilgor RS; Allen LM; Duvic M
Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
[TBL] [Abstract][Full Text] [Related]
2. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study.
Russell IJ; Lessard JA
J Rheumatol; 1985 Feb; 12(1):94-8. PubMed ID: 3884807
[TBL] [Abstract][Full Text] [Related]
3. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
4. DIAS rounds. Nifedipine and prazosin in Raynaud's phenomenon.
Pisenti L; Hart LL
Drug Intell Clin Pharm; 1984 Mar; 18(3):213-4. PubMed ID: 6365494
[No Abstract] [Full Text] [Related]
5. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Raynaud's phenomenon with captopril.
Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
[TBL] [Abstract][Full Text] [Related]
7. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
[TBL] [Abstract][Full Text] [Related]
8. [Nicardipine in the treatment of Raynaud's phenomenon].
Kahan A; Amor B; Menkès CJ
Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
[TBL] [Abstract][Full Text] [Related]
9. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
[TBL] [Abstract][Full Text] [Related]
11. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
12. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000956. PubMed ID: 10796398
[TBL] [Abstract][Full Text] [Related]
13. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
14. [The use of Capoten in systemic scleroderma].
Guseva NG; Anikina NV; Shcherbakov AB
Ter Arkh; 1992; 64(5):100-2. PubMed ID: 1455361
[TBL] [Abstract][Full Text] [Related]
15. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
16. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
Kahan A; Amor B; Menkes CJ
Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
[TBL] [Abstract][Full Text] [Related]
17. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
Rhedda A; McCans J; Willan AR; Ford PM
J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
[TBL] [Abstract][Full Text] [Related]
18. Prazosin treatment of primary Raynaud's phenomenon.
Nielsen SL; Vitting K; Rasmussen K
Eur J Clin Pharmacol; 1983; 24(3):421-3. PubMed ID: 6345178
[TBL] [Abstract][Full Text] [Related]
19. Nifedipine and Raynaud's phenomenon associated with connective tissue diseases.
Kahan A; Weber S; Amor B; Menkes CJ; Hodara M; Degeorges M
Int Angiol; 1985; 4(2):221-3. PubMed ID: 3831143
[TBL] [Abstract][Full Text] [Related]
20. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
